Financial Data and Key Metrics Changes - In Q1 2025, the company reported revenue of $6.75 million, a 17% increase year over year driven by recurring revenue growth from B2B2C channels [11] - Non-GAAP gross margins improved to 70.5%, up from 62.4% in Q1 2024, with core B2B2C business sustaining above 81% gross margins for four consecutive quarters [14][37] - Non-GAAP operating loss decreased from $9.1 million to $5.8 million year over year, representing a 36% reduction [14] Business Line Data and Key Metrics Changes - The company signed 14 new clients in Q1 2025, including one national health plan, one regional health plan, and 12 employers, increasing the total client base to 97 from 83 at the end of 2024 [13][21] - Over 80% of new contracts are multi-condition, with an average contract length of three years and a renewal rate above 90% [13][21] Market Data and Key Metrics Changes - The market is shifting towards whole person digital health and platform consolidation, with employers and health plans seeking trusted partners for multi-condition care [9][22] - The company is actively engaged with multiple national and regional payers, with two top-tier health plans evaluating the full suite platform for deployment in 2026 [27][28] Company Strategy and Development Direction - The company is focused on executing a strategy centered on platform differentiation, client quality, and commercial scalability, leveraging AI to enhance operational efficiency and member engagement [15][33] - The integration of Twilio has strengthened the company's position in the industry, allowing it to support five chronic conditions under a unified brand [7][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving operational cash flow breakeven run rate by the end of 2025, supported by existing account extensions and a deep pipeline of near-term opportunities [19][38] - The company is optimistic about the reset in the digital health market, emphasizing the importance of clinical credibility and financial discipline [38][40] Other Important Information - The company completed an equity raise and refinanced its debt, deferring debt amortization to 2028, which provides financial flexibility [19] - The leadership team has been strengthened with new appointments, enhancing execution and cross-functional alignment [18] Q&A Session Summary Question: Can you explain the timeline delays related to tariffs? - Management indicated that delays were due to a large account transforming its offering and some specific partnerships affected by tariff issues, which impacted revenue expectations [44][45] Question: How is the partnership with RULA Health rolling out? - The integration with RULA Health is underway, with initial adoption by a few clients and plans for broader campaigns [51][52] Question: What will drive the path to cash flow breakeven? - Achieving breakeven will be a combination of revenue growth and further reductions in operating expenses, with a focus on increasing gross margins from B2B2C business [54][56] Question: Can you provide an update on large pharma activities? - The company has signed new deals with large pharma companies, including Sanofi, and expects these to contribute revenue in Q2 or Q3 [62][65] Question: What is the impact of cleaning up contracts on revenue? - Most contracts are renewed, but transitioning to different revenue models for some accounts has created temporary headwinds [70][72]